My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Eisai Ltd ADR (OP:ESALY)

N/A UNCHANGED

Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Eisai Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >

Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial ↗

November 11, 2021

Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) announced results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across...

Via Benzinga

The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts ↗

November 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &...

Via Benzinga

Chinese Growth Level ↗

October 18, 2021

The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues.

Via Talk Markets

Europe's Unicorns ↗

October 15, 2021

After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit.

Via Talk Markets

Multiple Bits Of Bad News ↗

September 28, 2021

Republican debt ceiling brinkmanship boosted yields way over what stocks can pay, with info-tech the big loser.

Via Talk Markets

Eisai, Biogen Initiate Rolling Submission For New Alzheimer's Drug ↗

September 28, 2021

Eisai Co Ltd (OTC: ESALY) began its application process for lecanemab (BAN2401) for early Alzheimer's disease using an accelerated approval pathway. Lecanemab...

Via Benzinga

A Day Of Huge Market Moves ↗

September 21, 2021

It was a day of huge market moves and several reporting companies. Trudeau won but did not get a parliamentary majority.

Via Talk Markets

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive ↗

September 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...

Via Benzinga

Pressure Day ↗

September 13, 2021

Today a recovery came to markets with a particular impact on uranium shares.

Via Talk Markets

A Weak Week ↗

September 10, 2021

Chinese car-maker Nio appears to have been able to weather the Beijing crackdown on foreign listed firms better than later entrants.

Via Talk Markets

Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential ↗

September 10, 2021

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Via Benzinga

Dr Reddy's To Sell Its Anti-Cancer Agent To Citius Pharma ↗

September 07, 2021

Citius Pharmaceuticals Inc has agreed to acquire anti-cancer agent E7777 from Dr. Reddy's Laboratories Ltd (NYSE: RDY). E7777 is an engineered IL-2-...

Via Benzinga

Mu - The Newest Worry ↗

September 03, 2021

Today London and New York fell on the huge drop in new employment levels in August.

Via Talk Markets

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical ↗

August 31, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

Amid Medicare Uncertainty, Biogen Offers Its Alzheimer's Drug For Free ↗

August 30, 2021

Biogen Inc (NASDAQ: BIIB) is providing its controversial and expensive new Alzheimer's drug, free of charge for some patients amid slow claim reviews by Medicare, ...

Via Benzinga

The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In A Light Week ↗

August 29, 2021

Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. and BioNTech SE. The stocks subsequently moved back and...

Via Talk Markets

The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week ↗

August 29, 2021

Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. (NYSE: PFE) and BioNTech SE (...

Via Benzinga

What This Label Expansion Means for Merck ↗

August 22, 2021

The Keytruda-Lenvima combo was recently approved for its second oncology indication.

Via The Motley Fool

White House Dismisses Janet Woodcock As Permanent FDA Commissioner Candidate: Bloomberg ↗

August 20, 2021

The Biden Administration has ruled out the nomination of acting FDA commissioner Janet Woodcock as permanent head of the agency, Bloomberg reported citing people...

Via Benzinga

Controversial Aduhelm To Administered At More Than 300 Hospitals: Nikkei's ↗

August 17, 2021

Eisai Co Ltd (OTC: ESALY) and its U.S. partner Biogen Inc's (NASDAQ: BIIB) Alzheimer's treatment Aduhelm (aducanumab) will be used by more than 300...

Via Benzinga

The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow ↗

August 15, 2021

Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among...

Via Talk Markets

Topics Initial Public Offering

The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow ↗

August 15, 2021

Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small-...

Via Benzinga

Topics Initial Public Offering

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗

August 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...

Via Benzinga

Biogen's New Alzheimer's Drug Turned Away By Veterans Affairs ↗

August 12, 2021

The Department of Veterans Affairs (VA) has decided not to include the new Alzheimer's drug developed by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC:...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates ↗

August 02, 2021

The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi...

Via Benzinga

News Overload ↗

July 29, 2021

Today US markets managed a rally despite misses in both the growth and employment data.

Via Talk Markets

Full News Day ↗

July 28, 2021

The US greatly increased its exports of liquified natural gas in the first half-year, to 9.6 billion cubic feet per day, a rise of 42% from a year earlier.

Via Talk Markets

Topics Energy

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs ↗

July 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients ↗

July 27, 2021

An analysis of Phase 3 data presented by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) of its Alzheimer's therapy Aduhelm (aducanumab) ...

Via Benzinga

Containment Plan ↗

July 23, 2021

Today the US decided to cut China risks.

Via Talk Markets

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.